Advances in Chronic Kidney Disease
Volume 11, Issue 3 , Pages 274-293 , July 2004

Impact of kidney transplantation on the progression of cardiovascular disease

  • Sangeetha Satyan

      Affiliations

    • Department of Medicine, Division of Nephrology, William Beaumont Hospital, Royal Oak, MI, USA
    • ,
  • Leslie L Rocher

      Affiliations

    • Department of Medicine, Division of Nephrology, William Beaumont Hospital, Royal Oak, MI, USA
    • Corresponding Author InformationAddress correspondence to Leslie L. Rocher, MD, Department of Medicine, Medical Administration Building, William Beaumont Hospital, 3601 West Thirteen Mile Road, Royal Oak, MI 48073 USA

References 

  1. Strong JP, Malcom GT, McMahan CA, et al.  Prevalence and extent of atherosclerosis in adolescents and young adults (Implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study). JAMA. 1999;281:727–735
  2. Tuzcu EM, Kapadia SR, Tutar E, et al.  High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults (Evidence from intravascular ultrasound). Circulation. 2001;103:2705–2710
  3. Celermajer DS, Serensen KE, Bull C, et al.  Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24:1468–1474
  4. Ross R. The Pathogenesis of atherosclerosis (A perspective for the 1990s). Nature. 1993;362:801–809
  5. Kiechl S, Willeit J. The natural course of atherosclerosis: Part II: Vascular remodeling. Arterioscler Thromb Vasc Biol. 1999;19:1491–1498
  6. Schoenhagen P, Ziada KM, Vince DG, et al.  Arterial remodeling and coronary artery disease (The concept of “dilated” versus “obstructive” coronary atherosclerosis). J Am Coll Cardiol. 2001;38:297–306
  7. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143
  8. Ross R. Mechanisms of disease (Atherosclerosis—an inflammatory disease). N Engl J Med. 1995;340:115–126
  9. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(suppl):S112
  10. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(suppl):S16–S23
  11. USRDS Annual Data Report 2003. 2003; Available at: www.usrds.org. Accessed November
  12. Howard RJ, Patton PR, Reed AI, et al.  The changing causes of graft loss and death after kidney transplantation. Transplantation. 2002;73:1923–1928
  13. Meier-Kriesche H, Ojo AO, Port FK, et al.  Survival improvement among patients with end-stage renal disease (Trends over time for transplant recipients and wait-listed patients). J Am Soc Nephrol. 2001;12:1293–1296
  14. Aker S, Ivens K, Guo Z, et al.  Cardiovascular complications after renal transplantation. Transplant Proc. 1998;30:2039–2042
  15. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant. 1999;14:648–654
  16. Ojo AO, Hanson JA, Wolfe RA, et al.  Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57:307–313
  17. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med. 1988;84:985–992
  18. Kasiske BL, Guijarro C, Massy ZA, et al.  Cardiovascular disease after renal transplantation. J Am Soc Nephrol. 1996;7:158–165
  19. Adams HP, Dawson G, Coffman TJ, et al.  Stroke in renal transplant recipients. Arch Neurol. 1986;43:113–115
  20. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000;11:1735–1743
  21. Sung RS, Althoen M, Howell TA, et al.  Peripheral vascular occlusive disease in renal transplant recipients (Risk factors and impact on kidney allograft survival). Transplantation. 2000;70:1049–1054
  22. Oliveras A, Roquer J, Puig JM, et al.  Stroke in renal transplant recipients (Epidemiology, predictive risk factors and outcome). Clin Transplant. 2003;17:1–8
  23. Heart Disease and Stroke Statistics—2003 Update. American Heart Association. 2003; Available at www.americanheart.org. Accessed August
  24. Shepherd J, Cobbe SM, Ford I, et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301
  25. Downs JR, Clearfield M, Weis S, et al.  AFCAPS/TexCAPS Research Group   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels (Results of AFCAPS/TexCAPS). JAMA. 1998;279:1615
  26. Sacks FM, Pfeffer MA, Moye LA, et al.  Cholesterol and Recurrent Events Trial investigators   The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001
  27. Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease (The Scandinavian Simvastatin Survival Study (4S)). Lancet. 1994;344:1383–1389
  28. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke (Systematic review and meta-analysis). BMJ. 2003;326:1–7
  29. Dennis L, Sprecher MD. Triglycerides as a risk factor for coronary artery disease. Am J Cardiol. 1998;82:49U–56U
  30. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease (Meta-analysis of prospective studies). Circulation. 2000;102:1082–1085
  31. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease (A critical review of the evidence). JAMA. 2003;290:932–940
  32. Mortazavi M, Tohidi M, Rahbani-Nobar M. Evaluation of serum levels of lipids and lipoproteins in kidney-transplanted patients. Transplant Proc. 2001;33:2689–2690
  33. Bertram L, Kasiske MD. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32(suppl):S142–S156
  34. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation. 1997;63:331–338
  35. Kasiske BL, Vazquez MA, Harmon WE, et al.  Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. [In Process Citation] J Am Soc Nephrol. 2000;11(suppl 15):S1
  36. Moore RA, Callahan MF, Cody M, et al.  The effect of the American Heart Association step one diet on hyperlipidemia following renal transplantation. Transplantation. 1990;49:60–62
  37. US Department of Health and Human Services Public Health Service National Institutes of Health, National Heart, Lung, and Blood Institute . Third Report of the National Cholesterol Education Program (NCEP): Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final report. Circulation. 2002;106:3143
  38. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. 2004; Available at www.kidney.org. Accessed January
  39. Lepre F, Rigby R, Hawley C, et al.  A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. Clin Transplant. 1999;13:521–526
  40. Ballantyne CM, Radovancevic B, Farmer JA, et al.  Hyperlipidemia after heart transplantation (Report of a 6-year experience, with treatment recommendations). J Am Coll Cardiol. 1992;19:1315–1321
  41. Cofan F, Gilabert R, Zambon D, et al.  Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplant Proc. 2002;34:384–388
  42. Holdaas H, Fellstrom B, Jardine AG, et al.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients (a multicentre, randomised, placebo-controlled trial). Lancet. 2003;361:2024–2031
  43. Wilson PW, D’Agostino RB, Sullivan L, et al.  Overweight and obesity as determinants of cardiovascular risk (The Framingham experience). Arch Intern Med. 2002;162:1867
  44. Calle EE, Thun MJ, Petrelli JM, et al.  Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097
  45. Lakka HM, Laaksonen DE, Lakka TA, et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709
  46. Powell KE, Thompson PD, Cespersen CJ, et al.  Physical activity and the incidence of coronary heart disease. Annu Rev Public Health. 1987;8:253
  47. Williamson DF, Pamuk E, Thun M, et al.  Prospective study of intentional weight-loss and mortality in never-smoking overweight US white women aged 40–64. Am J Epidemiol. 1995;141:1128
  48. Leon AS, Connett J, Jacobs DR, et al.  Leisure-time physical activity levels and risk of coronary heart disease and death. The Multiple Risk Factor Intervention Trial. JAMA. 1987;258:2388
  49. Fletcher GF, Balady GJ, Amsterdam EA, et al.  Exercise standards for testing and training (a statement for healthcare professionals from the American Heart Association). Circulation. 2001;104:1694–1740
  50. Fletcher GF, Balady G, Blair SN, et al.  Statement on exercise: Benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council in Clinical Cardiology, American Heart Association. Circulation. 1996;94:857
  51. Smith JK, Dykes R, Douglas JE, et al.  Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA. 1999;281:1722
  52. Friedman AN, Miskulin DC, Rosenberg IH, et al.  Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis. 2003;41:480–487
  53. Hjelmasaeth J, Hartmann A, Midtvedt K, et al.  Metabolic cardiovascular syndrome after renal transplantation. Nephrol Dial Transplant. 2001;16:1047–1052
  54. Baum CL, Thielke K, Westin E, et al.  Predictors of weight gain and cardiovascular risk in a cohort of racially diverse kidney transplant recipients. Nutrition. 2002;18:139–146
  55. Clunk JM, Lin CY, Curtis JJ. Variables affecting weight gain in renal transplant recipients. Am J Kidney Dis. 2001;38:349–353
  56. Johnson CP, Gallagher-Lepak S, Zhu YR, et al.  Factors influencing weight gain after renal transplantation. Transplantation. 1993;56:822–827
  57. Teplan V, Poledne R, Schuck O, et al.  Hyperlipidemia and obesity after renal transplantation. Ann Transplant. 2001;6:21–23
  58. Modlin CS, Flechner SM, Goormastic M, et al.  Should obese patients lose weight before receiving a kidney transplant?. Transplantation. 1997;64:599
  59. Jurewicz WA, Baboolal K. Obesity and transplantation. Transplantation 2002. 2002;74:600–601
  60. Halme L, Eklund B, Kyllonen L, et al.  Is obesity still a risk factor in renal transplantation?. Transpl Int. 1997;10:284
  61. Meier-Kriesche H, Vaghela M, Thambuganipalle R, et al.  The effect of body mass index on long-term renal allograft survival. Transplantation. 1999;68:1294–1297
  62. Lopes IM, Martin M, Errasti P, et al.  Benefits of a dietary intervention on weight loss, body composition, and lipid profile after renal transplantation. Nutrition. 1999;15:7–10
  63. Patel MG. The effect of dietary intervention on weight gains after renal transplantation. J Ren Nutr. 1998;8:137–141
  64. Prospective Studies Collaboration . Age-specific relevance of usual blood pressure to vascular mortality (A meta-analysis of individual data for one million adults in 61 prospective studies). Lancet. 2002;360:1903–1913
  65. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet. 2000;356:1955–1964
  66. Ogden LG, He J, Lydick E, et al.  Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35:539–543
  67. Mange K, Cizman B, Joffe M, et al.  Arterial hypertension and renal allograft survival. JAMA. 2000;283:633–638
  68. First MR, Neylan JF, Rocher LL, et al.  Hypertension after renal transplantation. J Am Soc Nephrol. 1994;4(8 suppl):S30–S36
  69. Zeier M, Mandelbaum A, Ritz E. Hypertension in the transplanted patient. Nephron. 1998;80:257–268
  70. Perez Fontan M, Rodriguez-Carmona A, Garcia Falcon T, et al.  Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation. Am J Kidney Dis. 1999;33:21–28
  71. Kasiske BL, Ballantyne CM. Cardiovascular risk associated with immunosuppression in renal transplantation. Transplant Rev. 2002;16:1–21
  72. Guidi E, Menghetti D, Milani S, et al.  Hypertension may be transplanted with the kidney in humans (A long-term historical perspective follow-up of recipients grafted with kidneys coming from donors with or without hypertension in their families). J Am Soc Nephrol. 1996;7:113
  73. Bales GT, Fellner SK, Chodak GW, et al.  Laparoscopic bilateral nephrectomy for renin-mediated hypertension. Urology. 1994;43:874–877
  74. Huysmans FT, van Heusden FH, Wetzels JF, et al.  Antihypertensive effect of beta-blockade in renal transplant recipients with or without host kidneys. Transplantation. 1988;46:234–238
  75. Midtvedt K, Hartmann A, Foss A, et al.  Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation. 2001;72:1787–1792
  76. Ruggenenti P, Perrna A, Benini R, et al.  Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition and blood pressure control on chronic non-diabetic nephropathies. J Am Soc Nephrol. 1998;9:2096–2101
  77. Lake KD. Management of drug interactions with cyclosporine. Pharmacotherapy. 1991;11(suppl):110S–118S
  78. Stigant CE, Cohen J, Vivera M, et al.  ACE inhibitors and angiotensin 2 antagonists in renal transplantation (an analysis of safety and efficacy). Am J Kidney Dis. 2000;35:58–63
  79. Sennesael J, Lamote J, Violet I, et al.  Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. Hypertension. 1995;26:436–444
  80. Hausberg M, Barenbrock M, Hohage H, et al.  ACE inhibitor versus β-blocker for the treatment of hypertension in renal allograft recipients. Hypertension. 1999;33:862–868
  81. Mourad G, Vela C, Ribstein J, et al.  Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Clin Transplant. 1998;65:661–667
  82. Pascual M, Curtis J, Delmonico F, et al.  A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation. 2003;75:1501–1505
  83. Artz MA, Boots JMM, Ligtenberg G, et al.  Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol. 2003;14:1880–1888
  84. Johnson RWG, Kreis H, Oberbauer R, et al.  Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 2001;72:777–786
  85. Oberbauer R, Kreis H, Johnson RWG, et al.  Rapamune Maintenance Regimen Study Group   Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients (2-year results of the rapamune maintenance regimen study). Transplantation. 2003;76:364–370
  86. Fervenza FC, Lafayette RA, Alfrey EJ, et al.  Renal artery stenosis in kidney transplants. Am J Kidney Dis. 1998;31:142–148
  87. Fricke L, Doehn C, Steinhoff J, et al.  Treatment of posttransplant hypertension by laparoscopic bilateral nephrectomy?. Transplantation. 1998;65:1182–1187
  88. Elliott MD, Kapoor A, Michele A, et al.  Improvement in hypertension in patients with diabetes mellitus after kidney/pancreas transplantation. Circulation. 2001;104:563–569
  89. Grundy SM, Benjamin IJ, Burke GL, et al.  Diabetes and cardiovascular disease (A statement for healthcare professionals from the American Heart Association). Circulation. 1999;100:1134
  90. Coutinho M, Gerstein HC, Wang Y, et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233–240
  91. Makita Z, Bucala R, Rayfield EJ, et al.  Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet. 1994;343:1519
  92. Yoshida S, Yamada K, Hamaguchi K, et al.  Immunohistochemical study of human advanced glycation end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with kidney transplantation. Clin Nephrol. 1998;49:273–280
  93. Wolfe RA, Ashby VB, Milford EL, et al.  Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725
  94. Arend SM, Mallat MJ, Westendorp RJ, et al.  Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant. 1997;12:1672–1679
  95. Rischen-Vos J, van der Woude FJ, Tegzess AM, et al.  Increased morbidity and mortality in patients with diabetes mellitus after kidney transplantation as compared with non-diabetic patients. Nephrol Dial Transplant. 1992;7:433–437
  96. Hirsch MMK, Derfler K, Heinz G, et al.  Long-term follow-up of renal transplantation in type 1 and type 2 diabetic patients. Clin Invest. 1992;70:917–921
  97. Munson JL, Bennett WM, Barry JM, et al.  A case control study of renal transplantation in patients with type 1 diabetes. Clin Transplant. 1992;6:306–311
  98. von Kiparski A, Frei D, Uhlschmid G, et al.  Post-transplant diabetes mellitus in renal allograft recipients (A matched-pair control study). Nephrol Dial Transplant. 1990;5:220–225
  99. Jindal RM, Hjelesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation. 2000;70(11 suppl):SS58–SS63
  100. Montori VM, Velosa JA, Basu A, et al.  Posttransplantation diabetes (A systematic review of the literature). Diabetes Care. 2002;25:583
  101. Fernandez-Fresnedo G, Escallada R, de Francisco ALM, et al.  Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant Proc. 2003;35:700
  102. Davidson J, Wilkinson A, Dantal J, et al.  New-onset diabetes after transplantation (2003 International Consensus Guidelines). Transplantation. 2003;75:SS3–SS24
  103. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Available at http://www.nzgg.org.nz/library/gl_complete/diabetes/who_report_diabetes_diagnosis-.pdf
  104. American Diabetes Association . Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(suppl 1):S5
  105. Marchetti P. Strategies for risk reduction and management of posttransplant diabetes mellitus. Transplant Proc. 2001;33:27S–31S
  106. The Diabetes Control and Complications Research Group . Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75:894
  107. Epidemiology of Diabetes Interventions and Complications Research Group . Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes. 1999;48:383
  108. The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977
  109. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837
  110. Stratton IM, Adler AI, Neil HAW, et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) (Prospective observational study). BMJ. 2000;321:405–412
  111. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. The JNC 7 report. JAMA. 2003;289:2560
  112. Mogensen CE. Combined high blood pressure and glucose in type 2 diabetes (Double jeopardy). (editorial) BMJ. 1998;317:693
  113. UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317:703
  114. Bunnapradist S, Cho YW, Cecka JM, et al.  Kidney allograft and patient survival in type I diabetic recipients of cadaveric kidney alone versus simultaneous pancreas/kidney transplants (A multivariate analysis of the UNOS database). J Am Soc Nephrol. 2003;14:208
  115. Ojo AJ, Meier-Kriesche HU, Arnodorfer JA, et al.  Long-term benefit of kidney-pancreas transplants in type 1 diabetics. Transplant Proceed. 2001;33:1670–1672
  116. Fiorina P, Folli F, Maffi P, et al.  Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation (A comparison between kidney-pancreas and kidney-alone transplantation). Transplantation. 2003;75:1296–1301
  117. Fiorina P, La Rocca E, Venturini M, et al.  Effects of kidney-pancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and type 1 diabetes. Diabetes. 2001;50:3428–3434
  118. Manske CL, Wilson RF, Wang Y, et al.  Atherosclerotic vascular complications in diabetic transplant candidates. Am J Kidney Dis. 1997;29:601–607
  119. Manske CL, Wang Y, Rector T, et al.  Coronary revascularization in insulin-dependent diabetic patients with chronic renal failure. Lancet. 1992;40:998
  120. Koch M, Gradaus F, Schoebel FC, et al.  Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol Dial Transplant. 1997;12:1187
  121. Lawrence de Koning LAB, Werstuck GH, Zhou J, et al.  Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem. 2003;36:431–441
  122. Boushey CJ, Beresford SAA, Omenn GS, et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease (Probable benefits of increasing folic acid intakes). JAMA. 1995;274:1049–1057
  123. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease (Evidence on causality from a meta-analysis). BMJ. 2002;325:1202–1206
  124. Homocysteine Studies Collaboration . Homocysteine and risk of ischemic heart disease and stroke (A meta-analysis [review]). JAMA. 2002;288:2015–2022
  125. Schnyder G, Roffi M, Pin R, et al.  Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345:1593–1600
  126. Ducloux D, Motte G, Challier B, et al.  Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients (A prospective study). J Am Soc Nephrol. 2000;11:134–137
  127. Arnadottir M, Hultberg B, Vladov V, et al.  Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation. 1996;61:509–512
  128. Ducloux CR, Gibey R, Vautrin P, et al.  Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients. Nephrol Dial Transplant. 1998;13:2890–2893
  129. Beaulieu AJ, Gohh RY, Han H, et al.  Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscler Thromb Vasc Biol. 1999;19:2918–2921
  130. Bostom AG, Gohh RY, Beaulieu AJ, et al.  Treatment of hyperhomocysteinemia in renal transplant recipients (A randomized, placebo-controlled trial). Ann Intern Med. 1997;127:1089–1092
  131. Marcucci R, Zanazzi M, Bertoni E, et al.  Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation. 2003;75:1551–1555
  132. Jee SH, Suh I, Kim IS, et al.  Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol (the Korea Medical Insurance Corporation Study). JAMA. 1999;282:2149
  133. Qiao Q, Tervahauta M, Nissinen A, et al.  Mortality from all causes and from coronary heart disease related to smoking and changes in smoking during a 35-year follow-up of middle-aged Finnish men. Eur Heart J. 2000;21:1621
  134. Wilson K, Gibson N, Willan A, et al.  Effect of smoking cessation on mortality after myocardial infarction (meta-analysis of cohort studies). Arch Intern Med. 2000;160:939
  135. Kawachi I, Colditz GA, Stampfer MJ, et al.  Smoking cessation and the decreased risk of stroke in women. JAMA. 1993;269:232
  136. Hughes JR, Goldstein MG, Hurt RD, et al.  Recent advances in the pharmacotherapy of smoking. JAMA. 1999;281:72–76
  137. Silagy C, Mant D, Fowler G, et al.  Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet. 1994;343:139–142
  138. U.S. Department of Health and Human Services . Smoking cessation (Information for specialists). Rockville, Maryland: Agency for Health Care Policy and Research; 1996; Publication No. 96–0694
  139. Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol. 2000;11:753–759
  140. Cosio FG, Falkenhain ME, Pesavento TE, et al.  Patient survival after renal transplantation: II. The impact of smoking. Clin Transplant. 1999;13:336–341
  141. Nankivell BJ, Lau SG, Chapman JR, et al.  Progression of macrovascular disease after transplantation. Transplantation. 2000;69:574–581
  142. Ridker PM, Cushman M, Stampfer MJ, et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  143. Ridker PM, Rifai N, Rose L, et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  144. Ridker PM, Rifai N, Pfeffer MA, et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839–844
  145. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease (A critical review of the evidence). JAMA. 2003;290:932–940
  146. Ridker PM, Bassuk SS, Toth PP. C-reactive protein and risk of cardiovascular disease (Evidence and clinical application). Curr Atheroscler Rep. 2003;5:341–349
  147. Fink JC, Onuigbo MA, Blahut SA, et al.  Pre-transplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients (A pilot case-control study). Am J Kidney Dis. 2002;39:1096–1101
  148. Reek C, Conrad S, Tenschert W, et al.  Do serum C-reactive protein measurements help to discriminate episodes of renal dysfunction in patients after renal transplantation?. Clin Chim Acta. 2001;310:57–61
  149. Humar A, Gillingham K, Payne WD, et al.  Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation. 2000;70:310–313
  150. Hernandez D, Hanson E, Kasiske MK, et al.  Cytomegalovirus disease is not a major risk factor for ischemic heart disease after renal transplantation. Transplantation. 2001;72:1395–1399
  151. Kalil RSN, Hudson SL, Gaston RS. Determinants of cardiovascular mortality after renal transplantation (A role for cytomegalovirus?). Am J Transplant. 2003;3:79–81
  152. Muller J, Nyvad O, Larsen NA, et al.  Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in dialysis patients, renal transplant recipients and healthy controls. Scand J Clin Lab Invest. 2002;62:503–510
  153. Prasad A, Zhu J, Halcox JPJ, et al.  Predisposition to atherosclerosis by infections (role of endothelial dysfunction). Circulation. 2002;106:184–190
  154. Muhlestein JB, Hammond EH, Carlquist JF, et al.  Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol. 1995;27:1555–1561
  155. Pasceri V, Cammarota G, Patti G, et al.  Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation. 1998;97:1675–1679
  156. Smieja M, Gnarpe J, Lonn E, et al.  Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107:251–257
  157. Sorlie PD, Nieto FJ, Adam E, et al.  A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease (The Atherosclerosis Risk in Communities (ARIC) study). Arch Intern Med. 2000;160:2027–2032
  158. Adler SP, Hur JK, Wang JB, et al.  Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis. 1998;177:209–212
  159. Muhlestein JB, Horne BD, Carlquist JF, et al.  Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation. 2000;102:1917
  160. Grayston JT. Antibiotic treatment of atherosclerotic cardiovascular disease. Circulation. 2003;107:1228–1230
  161. O’Connor CM, Dunne MW, Pfeffer MA, et al.  Azithromycin for the secondary prevention of coronary heart disease events. The WIZARD study: A randomized controlled trial. JAMA. 2003;290:1459–1466
  162. Wickre CG, Norman DJ, Bennison A, et al.  Postrenal transplant erythrocytosis (A review of 53 patients). Kidney Int. 1983;23:731–737
  163. Gruppo ISP. Polycythemia vera (The natural history of 1213 patients followed for 20 years). Ann Intern Med. 1995;123:656–664
  164. Orlandi E, Castelli G, Brusamolino E, et al.  Hemorrhagic and thrombotic complications in polycythemia vera (A clinical study). Hematolgia. 1989;74:45–49
  165. Montanaro D, Groupuzzo M, Boscutti G, et al.  Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors (Efficacy, safety and action mechanisms). Clin Nephrol. 2000;53(suppl):47–51
  166. Julian BA, Brantley RRJ, Barker CV, et al.  Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol. 1998;9:1104–1108
  167. Yildiz A, Cine N, Akkaya SS, et al.  Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients (prospective randomized study). Transplantation. 2001;72:542
  168. Ma J, Hennekens CH, Ridker PM, et al.  A prospective study of fibrinogen and risk of myocardial infarction in the Physicians’ Health Study. J Am Coll Cardiol. 1999;33:1347
  169. Scarabin PY, Aillaud MF, Amouyel P, et al.  Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction—the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost. 1998;80:749
  170. Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA. 1987;258:1183–1186
  171. Ernst E. The role of fibrinogen as a cardiovascular risk factor. Atherosclerosis. 1993;100:1–12
  172. Irish AB, Green FR. Environemental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant. 1997;12:167–173
  173. Linde T, Sandhagen B, Backman U, et al.  Altered flow properties of blood and increased plasma fibrinogen in cyclosporin-treated renal allograft recipients. Nephrol Dial Transplant. 1999;14:1525–1529
  174. Van den Dorpel MA, Man’t Veld AJ, Levi M, et al.  Beneficial effects of conversion from cyclosporine to azathioprine on fibrinolysis in renal transplant recipients. Arterioscler Thromb Vasc Biol. 1999;19:1555–1558
  175. Sartori MT, Rigotti P, Marchini F, et al.  Plasma fibrinolytic capacity in renal transplant recipients (Effect of steroid-free immunosuppression therapy). Transplantation. 2003;75:994–998
  176. Malyszko J, Malyszko JS, Pawlak K, et al.  The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients. Transplantation. 1996;62:828–830
  177. Averna M, Barbagallo CM, Ganci A, et al.  Determinants of enhanced thromboxane biosynthesis in renal transplantation. Kidney Int. 2001;59:1574–1579
  178. Graff J, Klinkhardt U, Harder S, et al.  Immunosuppressive therapy regimen and platelet activation in renal transplant patients. Clin Pharmacol Ther. 2002;72:411–418
  179. Antiplatelet Trialists’ Collaboration . Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81–106
  180. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann Intern Med. 2002;136:157–160
  181. Mattock MB, Morrish NJ, Viberti G, et al.  Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992;41:736–741
  182. Gerstein HC, Mann JF, Yi Q, et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421
  183. Valmadrid CT, Klein R, Moss SE, et al.  The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160:1093
  184. Hillege HL, Fidler V, Diercks GF, et al.  Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777
  185. Miettinen H, Haffner SM, Lehto S, et al.  Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic patients. Stroke. 1996;27:2033
  186. Fernandez-Fresnedo G, Escallada R, Rodrigo E, et al.  The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation. 2002;73:1345–1348
  187. Roodnat JI, Mulder PGH, Rischen-Vos J, et al.  Proteinuria and death risk in renal transplant population. Transplant Proc. 2001;33:1170
  188. Mann JF, Gerstein HC, Yi QL, et al.  Development of renal disease in people at high cardiovascular risk (Results of the HOPE randomized study). J Am Soc Nephrol. 2003;14:641
  189. De Leeuw PW, Thijs L, Birkenhager WH, et al.  Prognostic significance of renal function in elderly patients with isolated systolic hypertension (Results from the Syst-Eur Trial). J Am Soc Nephrol. 2002;13:2213
  190. Mann JFE, Gerstein HC, Pogue J, et al.  renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril (The HOPE Randomized Trial). Ann Intern Med. 2001;134:629–636
  191. Muntner P, He J, Hamm L, et al.  Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745–753
  192. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation. 2003;75:1291–1295
  193. Kaplan B, Meier-Kriesche HU. Death after graft loss (An important late study endpoint in kidney transplantation). Am J Transplant. 2002;2:970–974
  194. Lemieux I, Houde I, Pascot A, et al.  Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients. Kidney Int. 2002;62:1839–1847
  195. Rigotti P and the European Tacrolimus/MMF Transplantation Study Group . Patients with high cholesterol levels benefit most from early withdrawal of corticosteroids. Transplant Proc. 2002;34:1797–1798
  196. Veenstra DL, Best JH, Hornberger J, et al.  Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis. 1999;33:829–839
  197. Hjelmasaeth J, Hartmann A, Kofstad J, et al.  Tapering off prednisolone and cyclosporin the first year after renal transplantation (The effect on glucose tolerance). Nephrol Dial Transplant. 2001;16:829–835
  198. Boots JMM, Christiaans MHL, van Duijnhoven EM, et al.  Early steroid withdrawal in renal transplantation with tacrolimus dual therapy (A pilot study). Transplantation. 2002;74:1703–1709
  199. Nowacka-Cieciura E, Durlik M, Cieciura T, Lewandowska D, et al.  Steroid withdrawal after renal transplantation-risks and benefits. Transplant Proc. 2002;34:560–563
  200. Kasiske BL, Tortorice KL, Heim-Duthoy KL, et al.  The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis. 1991;6:700–707
  201. Apanay DC, Neylan JF, Ragab MS, et al.  Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation. 1994;58:663–669
  202. Hohage H, Arlt M, Bruckner D, et al.  Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients. Clin Transplant. 1997;11:225
  203. Satterthwaite R, Aswad S, Sunga V, et al.  Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation. 1998;65:446
  204. McCune TR, Thacker LR, Peters TG, et al.  Effects of tacrolimus on hyperlipidemia after successful renal transplantation. Transplantation. 1998;65:87
  205. Boucher A, Masse M, Lauzon L, et al.  Impact of immunosuppressive regimen on cardiovascular risk factors in kidney transplant recipients. Transplant Proc. 2002;34:1799–1802
  206. Haas M, Mayer G. Cyclosporin A-associated hypertension—pathomechanisms and clinical consequences. Nephrol Dial Transplant. 1997;12:395–397
  207. Margreiter R and European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group . Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation (a randomised multicentre study). Lancet. 2002;359:741–748
  208. Tanabe K. Calcineurin inhibitors in renal transplantation. What is the best option?. Drugs. 2003;63:1535–1548
  209. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation (A randomised multicentre study). Lancet. 2002;359:741–746
  210. Rabkin JM, Corless CL, Rosen HR, et al.  Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg. 2002;183:595–599
  211. Vincenti F, Jensik SC, Filo RS, et al.  A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation (Evidence for improved allograft survival at five years). Transplantation. 2002;73:775–782
  212. Klein IHHT, Abrahams A, van Ede T, et al.  Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation. 2002;73:732–736
  213. Colak T, Karakayali H, Yagmurdur MC, et al.  Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients. Transplant Proc. 2002;34:2081–2082
  214. Artz MA, Boots JMM, Ligtenberg G, et al.  Randomized conversion from cyclosporine to tacrolimus in renal transplant patients (Improved lipid profile and unchanged plasma homocysteine levels). Transplant Proc. 2002;34:1793–1794
  215. Chueh SJ, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen (Incidence, risk factors, progression, and prognosis). Transplantation. 2003;76:375–382
  216. Ligtenberg G, Hene RJ, Blankestijn PJ, et al.  Cardiovascular risk factors in renal transplant patients (Cyclosporin A versus tacrolimus). J Am Soc Nephrol. 2001;12:368–373
  217. Arnadottir M, Hultberg B, Vladov V, et al.  Hyperhomocysteinemia in cyclosporine -treated renal transplant recipients. Transplantation. 1996;61:509–510
  218. Fernandez-Fresnedo G, Escallada R, de Francisco ALM, et al.  Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant Proc. 2003;35:700
  219. First MR, Gerber D, Hariharan S, et al.  Diabetes mellitus in kidney allograft recipients (Incidence, risk factors, and management). Transplantation. 2002;73:379–386
  220. Hohage H, Arlt M, Bruckner D, et al.  Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients. Clin Transplant. 1997;11:225–230
  221. Steinmuller TM, Graf KJ, Schleicher J, et al.  The effect of FK506 versus cyclosporine on glucose and lipid metabolism—a randomized trial. Transplantation. 1994;58:669–674
  222. Knoll GA, Bell RC. Tacrolimus vs. cyclosporine for immunosuppression in renal transplantation (Meta-analysis of randomised trials). BMJ. 1999;318:1104–1107
  223. Pirsch JD, Miller J, Deierhoi MH, et al.  FK506 Kidney Transplant Study Group   A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 1997;63:977–983
  224. Maes BD, Kuypers D, Messiaen T, et al.  Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients (Analysis of incidence and risk factors). Transplantation. 2001;72:1655–1661
  225. Arnadottir M, Hultberg B, Wahlberg J, et al.  Serum total homocysteine concentration before and after renal transplantation. Kidney Int. 1998;54:1380–1384
  226. Ducloux D, Fournier V, Rebibou JM, et al.  Hyperhomocysteinemia in renal transplant recipients with and without cyclosporine. Clin Nephrol. 1998;49:232–235
  227. Bostom AG, Gohh RY, Beaulieu AJ, et al.  Determinants of fasting plasma total homocysteine levels among chronic stable renal transplant recipients. Transplantation. 1999;68:257–261
  228. Wayman MR, Oniscu GC, Forsythe JLR, et al.  Two-year outcome in renal allograft recipients comparing neoral-led with tacrolimus-led therapy. Transplant Proc. 2002;34:1663–1665
  229. Ahsan N, Johnson C, Gonwa T, et al.  Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation (Results at 2 years). Transplantation. 2001;72:245–250
  230. Ovuworie C, Fox ER, Chow C, et al.  Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. Transplantation. 2001;72:1385–1388
  231. Abramowicz D, Manas D, Lao M, et al.  Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients (A randomized, controlled study). Transplantation. 2002;12:1725–1734
  232. Pascual M, Curtis J, Delmonico FL, et al.  A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation. 2003;75:1501–1505
  233. Chueh SJ, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen (Incidence, risk factors, progression, and prognosis). Transplantation. 2003;76:375–382
  234. Groth CG, Backman L, Morales JM, et al.  Sirolimus European Renal Transplant Study Group   Sirolimus (rapamycin)-based therapy in human renal transplantation (similar efficacy and different toxicity compared with cyclosporine). Transplantation. 1999;67:1036
  235. Gonwa T, Mendez R, Yang HC, et al.  Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation (Results at 6 months). Transplantation. 2003;75:1213–1220
  236. Legendre C, Campistol JM, Squifflet JP, et al.  Cardiovascular risk factors of sirolimus compared with cyclosporine (Early experience from two randomized trials in renal transplantation). Transplant Proc. 2003;35(suppl):151S–153S
  237. Flechner SM, Goldfarb D, Modlin C, et al.  Kidney transplantation without calcineurin inhibitor drugs (A prospective, randomized trial of sirolimus versus cyclosporine). Transplantation. 2002;74:1070–1076
  238. Rigatto C, Parfrey PS, Foley RN, et al.  Congestive heart failure in renal transplant recipients (Risk factors, outcomes, and relationship with ischemic heart disease). J Am Soc Nephrol. 2002;13:1084–1090
  239. Djamali A, Becker YT, Simmons WD, et al.  Increasing hematocrit reduces early posttransplant cardiovascular risk in diabetic transplant recipients. Transplantation. 2003;76:816–820
  240. Abbott KC, Yuan CM, Taylor AJ, et al.  Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol. 2003;14:2358–2365
  241. Abbott KC, Hypolite IO, Hshieh P, et al.  Hospitalized congestive heart failure after renal transplantation in the United States. Ann Epidemiol. 2002;12:115–122
  242. Parfrey PS, Harnett JD, Foley RN, et al.  Impact of renal transplantation on uremic cardiomyopathy. Transplantation. 1995;60:908–914
  243. Rigatto C, Foley RN, Kent GM, et al.  Long-term changes in left ventricular hypertrophy after renal transplantation. Transplantation. 2000;70:570–575
  244. Ferreira SRC, Moises VA, Tavares A, et al.  Cardiovascular effects of successful renal transplantation (A 1-year sequential study of left ventricular morphology and function, and 24-hour blood pressure profile). Transplantation. 2002;74:1580–1587
  245. Rigatto C, Foley R, Jeffery J, et al.  Electrocardiographic left ventricular hypertrophy in renal transplant recipients (prognostic value and impact of blood pressure and anemia). J Am Soc Nephrol. 2003;14:462–468
  246. Midtvedt K, Ihlen H, Hartmann A, et al.  Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients (A prospective randomized double-blind study). Transplantation. 2001;72:107–111

PII: S1548-5595(04)00079-5

doi: 10.1053/j.arrt.2004.04.010

Advances in Chronic Kidney Disease
Volume 11, Issue 3 , Pages 274-293 , July 2004

Article Tools

* Image Usage & Resolution